



**November
3rd - 4th, 2022
SORRENTO**

**THERAPEUTIC
ADVANCES IN PCa**

HILTON SORRENTO PALACE
Via Rivolo S. Antonio 13, Sorrento (NA)

Scientific Rationale

The treatment of prostate cancer is progressing fast as new evidence and new technologies are coming from research and clinical experience. The educational meeting "Therapeutic Advances in PCa" is intended to provide an overview of the latest therapeutic approach in any stage of the prostate cancer from localised, low risk to the advanced metastatic disease with an eye to the future perspectives which have the potential to improve clinical outcome and patients survival.

Scientific Director

Antonio Alcaraz Chairman Department of Urology, Hospital Clinic, Barcelona, Spain
Full professor of Urology, Department of Surgery, Universitat de Barcelona, Spain

Faculty

Antonio Alcaraz Chairman Department of Urology, Hospital Clinic, Barcelona, Spain
Full professor of Urology, Department of Surgery, Universitat de Barcelona, Spain

Alberto Bossi Head of the Urology and Prostate Brachytherapy Unit, Gustave Roussy Cancer Institute in Villejuif, France

Alberto Briganti Full Professor of Urology at the University Vita-Salute San Raffaele, Assistant Chief UO of Urology, IRCCS San Raffaele Hospital, Italy

Arnaldo Figueiredo Professor of Urology and Chairman of the Department of Urology and Transplantation, Hospital and University Center of Coimbra, Portugal

Ružica Maksimović Professor of Radiology, Faculty of Medicine, University of Belgrade, Serbia

Axel Merseburger Chairman of the Clinic of Urology, Department of Urology, University Hospital Schleswig-Holstein in Lübeck, Germany

Yann Neuzillet Head of University Sector, Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France

Derya Tilki Professor of Urology, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Thomas Wiegel Head of the Department of Radiotherapy and Radio-oncology, University Hospital of Ulm, Germany

Andrej Žist Department of Oncology, University Medical Centre Maribor, Slovenia

November 3rd

13:45-14:00 Welcome and introduction

Plenary session - Chairman: A. Alcaraz

14:00-14:20 New imaging in specific settings (early detection of metastasis in high risk PCa) *R. Maksimović*

14:20-14:40 Markers and precision medicine *A. Žist*

14:40-15:00 The role of ADT *A. Merseburger*

15:00-15:45 Five game changers in the management of PCa *A. Alcaraz*

15:45-17:00 **Breakout room 1** Management of localized disease (radiotherapy/surgery) *A. Briganti, T. Wiegel*

Breakout room 2 Management of recurrences after primary treatment *A. Bossi, Y. Neuzillet*

Breakout room 3 Clinical controversies in CRPC patients *A. Figueiredo, A. Žist*

Breakout room 4 HSPC disease *A. Merseburger, D. Tilki*

17:00-17:30 Coffee break

17:30-18:45 **Breakout room 1** Management of recurrences after primary treatment *A. Bossi, Y. Neuzillet*

Breakout room 2 Clinical controversies in CRPC patients *A. Figueiredo, A. Žist*

Breakout room 3 HSPC disease *A. Merseburger, D. Tilki*

Breakout room 4 Management of localized disease (radiotherapy/surgery) *A. Briganti, T. Wiegel*

November 4th

08:30-09:45 **Breakout room 1** Clinical controversies in CRPC patients *A. Figueiredo, A. Žist*

Breakout room 2 HSPC disease *A. Merseburger, D. Tilki*

Breakout room 3 Management of localized disease (radiotherapy/surgery) *A. Briganti, T. Wiegel*

Breakout room 4 Management of recurrences after primary treatment *A. Bossi, Y. Neuzillet*

09:45-11:00 **Breakout room 1** HSPC disease *A. Merseburger, D. Tilki*

Breakout room 2 Management of localized disease (radiotherapy/surgery) *A. Briganti, T. Wiegel*

Breakout room 3 Management of recurrences after primary treatment *A. Bossi, Y. Neuzillet*

Breakout room 4 Clinical controversies in CRPC patients *A. Figueiredo, A. Žist*

11:00-11:30 Coffee break

Plenary session - Chairman: A. Alcaraz

11:30-12:15 Management of lymph nodes in advanced and recurrent PCa *A. Briganti*

12:15-13:00 Take home message *A. Alcaraz*

UEMS-EACCME accreditation

LEE22-01396



The **Therapeutic Advances in PCa, Sorrento, Italy, 03/11/2022-04/11/2022** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **7 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20. In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

03.11.2022 - 4.00

04.11.2022 - 3.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

Provider CME and
secretariat

Supported by an unrestricted
educational grant from

EUREKA

 **RECORDATI**